Predictive value of MGMT, hMLH1, hMSH2 and BRCA1 protein expression for pathological complete response to neoadjuvant chemotherapy in basal-like breast cancer patients

Cancer Chemotherapy and Pharmacology

Volumn 69, Issue 4, 2012, Pages 923-930

  Nakai, Katsuya ^a   Mitomi, Hiroyuki ^a   Alkam, Yimit ^a   Arakawa, Atsushi ^a   Yao, Takashi ^a   Tokuda, Emi ^a   Saito, Mitsue ^a   Kasumi, Fujio ^a  

^a JUNTENDO UNIVERSITY   (Japan)

Author keywords

Basal like subtype; Breast cancer; Immunohistochemistry; MGMT; Mismatch repair; Neoadjuvant chemotherapy

Indexed keywords

ANTHRACYCLINE; BRCA1 PROTEIN; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PACLITAXEL; PROTEIN MLH1; PROTEIN MSH2; TAXANE DERIVATIVE;

ADULT; ADVANCED CANCER; ARTICLE; BREAST BIOPSY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SPECIFIC SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG RESPONSE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT RESPONSE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRCA1 PROTEIN; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; DNA MISMATCH REPAIR; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MUTS HOMOLOG 2 PROTEIN; NEOADJUVANT THERAPY; NEOPLASM STAGING; NUCLEAR PROTEINS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 84859789879     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-011-1777-7     Document Type: Article

References (38)

1. Kuerer HM, Newman LA, Smith TL, Ames FC, Hunt KK, Dhingra K, Theriault RL, Singh G, Binkley SM, Sneige N, Buchholz TA, Ross MI, McNeese MD, Buzdar AU, Hortobagyi GN, Singletary SE (1999) Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 17:460-469 (Pubitemid 29075229)
2. Chollet P, Amat S, Cure H, de Latour M, Le Bouedec G, Mouret-Reynier MA, Ferriere JP, Achard JL, Dauplat J, Penault-Llorca F (2002) Prognostic signiWcance of a complete pathological response after induction chemotherapy in operable breast cancer. Br J Cancer 86:1041-1046 (Pubitemid 34441058)
3. Kim MJ, Ro JY, Ahn SH, Kim HH, Kim SB, Gong G (2006) Clinicopathologic signiWcance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes. Hum Pathol 37:1217-1226 (Pubitemid 44286991)
4. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L, Akslen LA, Ragaz J, Gown AM, Gilks CB, van de Rijn M, Perou CM (2004) Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10:5367-5374 (Pubitemid 39100473)
5. Banerjee S, Reis-Filho JS, Ashley S, Steele D, Ashworth A, Lakhani SR, Smith IE (2006) Basal-like breast carcinomas: clinical outcome and response to chemotherapy. J Clin Pathol 59:729-735 (Pubitemid 44048783)
6. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687-1717
7. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673-1684 (Pubitemid 41464706)
8. Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML, Perou CM (2007) The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 13:2329-2334 (Pubitemid 46698581)
9. Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K, Hess KR, Stec J, Ayers M, Wagner P, Morandi P, Fan C, Rabiul I, Ross JS, Hortobagyi GN, Pusztai L (2005) Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 11:5678-5685 (Pubitemid 41170290)
10. Jiricny J (2006) The multifaceted mismatch-repair system. Nat Rev Mol Cell Biol 7:335-346
11. Pegg AE (2000) Repair of O(6)-alkylguanine by alkyl-transferases. Mutat Res 462:83-100
12. Ochs K, Kaina B (2000) Apoptosis induced by DNA damage O6-methylguanine is Bcl-2 and caspase-9/3 regulated and Fas/caspase-8 independent. Cancer Res 60:5815-5824
13. Mackay HJ, Cameron D, Rahilly M, Mackean MJ, Paul J, Kaye SB, Brown R (2000) Reduced MLH1 expression in breast tumors after primary chemotherapy predicts disease-free survival. J Clin Oncol 18:87-93 (Pubitemid 30036340)
14. Murata H, Khattar NH, Kang Y, Gu L, Li GM (2002) Genetic and epigenetic modiWcation of mismatch repair genes hMSH2 and hMLH1 in sporadic breast cancer with microsatellite instability. Oncogene 21:5696-5703 (Pubitemid 35333002)
15. Murata H, Khattar NH, Gu L, Li GM (2005) Roles of mismatch repair proteins hMSH2 and hMLH1 in the development of sporadic breast cancer. Cancer Lett 223:143-150 (Pubitemid 40693719)
16. Chintamani, Jha BP, Bhandari V, Bansal A, Saxena S, Bhatnagar D (2007) The expression of mismatched repair genes and their correlation with clinicopathological parameters and response to neo-adjuvant chemotherapy in breast cancer. Int Semin Surg Oncol 4:5
17. Clemons MJ, Bibby MC, El TeraiW H, Forster G, Kelly J, Banerjee S, Cadman B, Ryder WD, Howell A, Margison GP (2002) Heterogeneity of O6 alkylguanine DNA-alkyltransferase expression in human breast tumours. Br J Cancer 86:1797-1802 (Pubitemid 34712926)
18. Turner NC, Reis-Filho JS, Russell AM, Springall RJ, Ryder K, Steele D, Savage K, Gillett CE, Schmitt FC, Ashworth A, Tutt AN (2007) BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene 26:2126-2132 (Pubitemid 46514749)
19. Liu X, Holstege H, van der Gulden H, Treur-Mulder M, Zevenhoven J, Velds A, Kerkhoven RM, van Vliet MH, Wessels LF, Peterse JL, Berns A, Jonkers J (2007) Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1 mutated basal-like breast cancer. Proc Natl Acad Sci USA 104:12111-12116 (Pubitemid 47185638)
20. Farmer H, McCabe N, Lord CJ, Tutt ANJ, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C, Martin NM, Jackson SP, Smith GC, Ashworth A (2005) Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434:917-921 (Pubitemid 40559006)
21. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, Kyle S, Meuth M, Curtin NJ, Helleday T (2005) SpeciWc killing of BRCA2-deWcient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434:913-917 (Pubitemid 40559005)
22. Lord CJ, Ashworth A (2008) Targeted therapy for cancer using PARP inhibitors. Curr Opin Pharmacol 8:363-369
23. Sobin LH, Gospodarowicz MK, Wittekind Ch (eds) (2009) International Union Against Cancer (UICC) TNM classiWcation of malignant tumours, 7th edn. Wiley, Hoboken, pp 181-193
24. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
25. Lin Y, Lin S, Watson M, Trinkaus KM, Kuo S, Naughton MJ, Weilbaecher K, Fleming TP, Aft RL (2010) A gene expression signature that predicts the therapeutic response of the basal-like breast cancer to neoadjuvant chemotherapy. Breast Cancer Res Treat 123:691-699
26. Masuda H, Masuda N, Kodama Y, Ogawa M, Karita M, Yamamura J, Tsukuda K, Doihara H, Miyoshi S, Mano M, Nakamori S, Tsujinaka T (2010) Predictive factors for the effectiveness of neoadjuvant chemotherapy and prognosis in triple-negative breast cancer patients. Cancer Chemother Pharmacol. Jul 1 [Epub ahead of print]
27. Cayre A, Penault-Llorca F, De Latour M, Rolhion C, Feillel V, Ferrière JP, Kwiatkowski F, Finat-Duclos F, Verrelle P (2002) O(6)-methylguanine-DNA methyl transferase gene expression and prognosis in breast carcinoma. Int J Oncol 21:1125-1131
28. Matsukura S, Miyazaki K, Yakushiji H, Ogawa A, Harimaya K, Nakabeppu Y, Sekiguchi M (2001) Expression and prognostic signiWcance of O6-methylguanine-DNA methyltransferase in hepatocellular, gastric, and breast cancers. Ann Surg Oncol 8:807-816 (Pubitemid 34003330)
29. Osanai T, Takagi Y, Toriya Y, Nakagawa T, Aruga T, Iida S, Uetake H, Sugihara K (2005) Inverse correlation between the expression of O6-methylguanine-DNA methyl transferase (MGMT) and p53 in breast cancer. Jpn J Clin Oncol 35:121-125 (Pubitemid 40514540)
30. Everhard S, Kaloshi G, Crinière E, Benouaich-Amiel A, Lejeune J, Marie Y, Sanson M, Kujas M, Mokhtari K, Hoang-Xuan K, Delattre JY, Thillet J (2006) MGMT methylation: a marker of response to temozolomide in low-grade gliomas. Ann Neurol 60:740-743 (Pubitemid 46048490)
31. Crinière E, Kaloshi G, Laigle-Donadey F, Lejeune J, Auger N, Benouaich-Amiel A, Everhard S, Mokhtari K, Polivka M, Delattre JY, Hoang-Xuan K, Thillet J, Sanson M (2007) MGMT prognostic impact on glioblastoma is dependent on therapeutic modalities. J Neurooncol 83:173-179 (Pubitemid 46784990)
32. Esteller M, Gaidano G, Goodman SN, Zagonel V, Capello D, Botto B, Rossi D, Gloghini A, Vitolo U, Carbone A, Baylin SB, Herman JG (2002) Hypermethylation of the DNA repair gene O(6)-methylguanine DNA methyltransferase and survival of patients with diffuse large B-cell lymphoma. J Natl Cancer Inst 94:26-32
33. Gerson SL (2004) MGMT: its role in cancer aetiology and cancer therapeutics. Nat Rev Cancer 4:296-307
34. Clemons M, Kelly J, Watson AJ, Howell A, McElhinney RS, McMurry TB, Margison GP (2005) O6-(4-bromothenyl)guanine reverses temozolomide resistance in human breast tumour MCF-7 cells and xenografts. Br J Cancer 93:1152-1156 (Pubitemid 41670700)
35. Chekhun VF, Kulik GI, Yurchenko OV, Tryndyak VP, Todor IN, Luniv LS, Tregubova NA, Pryzimirska TV, Montgomery B, Rusetskaya NV, Pogribny IP (2006) Role of DNA hypomethylation in the development of the resistance to doxorubicin in human MCF-7 breast adenocarcinoma cells. Cancer Lett 231:87-93 (Pubitemid 41779456)
36. Rakha EA, El-Sheikh SE, Kandil MA, El-Sayed ME, Green AR, Ellis IO (2008) Expression of BRCA1 protein in breast cancer and its prognostic signiWcance. Hum Pathol 39:857-865
37. Margeli M, Cirauqui B, Castella E, Tapia G, Costa C, Gimenez-Capitan A, Barnadas A, Sanchez Ronco M, Benlloch S, Taron M, Rosell R (2010) The prognostic value of BRCA1 mRNA expression levels following neoadjuvant chemotherapy in breast cancer. PLoS One 5:e9499
38. Asakawa H, Koizumi H, Koike A, Takahashi M, Wu W, Iwase H, Fukuda M, Ohta T (2010) Prediction of breast cancer sensitivity to neoadjuvant chemotherapy based on status of DNA damage repair proteins. Breast Cancer Res 12:R17 (Epub 2010 Mar 5)